1. Association of Thromboembolic Risk Score with Left Atrial Thrombus and Spontaneous Echocardiographic Contrast in Non-Anticoagulated Nonvalvular Atrial Fibrillation Patients.
- Author
-
Huang J, Liao HT, Fei HW, Xue YM, Zhang L, Lin QW, Ren SQ, Zhan XZ, Fang XH, Zheng MR, Wu SL, and Xu L
- Subjects
- Aged, Aged, 80 and over, Atrial Fibrillation complications, Atrial Fibrillation diagnostic imaging, Atrial Function, Left, China epidemiology, Contrast Media, Echocardiography, Transesophageal, Heart Diseases, Humans, Male, Middle Aged, Multivariate Analysis, Risk Factors, Stroke etiology, Thrombosis complications, Thrombosis diagnostic imaging, Risk Assessment methods, Thromboembolism diagnostic imaging, Thromboembolism epidemiology, Thrombosis epidemiology
- Abstract
Objectives: The aim of the study was to examine the association of CHADS2/CHA2DS2-VASc scores with left atrial thrombus (LAT) and spontaneous echocardiographic contrast (SEC) in non-anticoagulated nonvalvular atrial fibrillation (NVAF) spontaneous patients, and to develop a new scoring system for LAT/SEC prediction., Methods: Consecutive non-anticoagulated NVAF patients with or without LAT/SEC by transesophageal echocardiography were identified in the Guangdong General Hospital., Results: Among 2,173 patients, the prevalence of LAT/SEC was 4.9%. Both predictive values of CHADS2 and CHA2DS2-VASc scores for the presence of LAT/SEC were low-to-moderate (receiver operating characteristic [ROC] = 0.591 and 0.608, respectively, p = 0.90). By multivariate analysis, non-paroxysmal AF, decreased left ventricular ejection fraction, and left atrial enlargement were positively associated with LAT/SEC, while CHADS2/CHA2DS2VASc scores were not. A new scoring system based on these 3 factors above significantly improved the discrimination for LAT/SEC (ROC = 0.792)., Conclusions: CHADS2/CHA2DS2-VASc scores had limited value in predicting LAT/SEC; a new scoring system that combines AF type and echocardiographic parameters may better predict LAT/SEC as a surrogate for cardioembolic risk in NVAF patients., (© 2018 S. Karger AG, Basel.)
- Published
- 2018
- Full Text
- View/download PDF